ArticleBMC cancer2022

Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis.

Hsiang-Fong Kao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.